Glycocholic acid
|
Basic information |
| Metabolite name | Glycocholic acid |
 | HMDB0000138 |
 |
C01921 |
 |
10140 |
| Synonyms | Sodium glycocholate; |
| No. of studies | 15 |
|
Basic information |
| Metabolite name | Glycocholic acid |
| HMDB0000138 |
|
C01921 |
|
10140 |
| Synonyms | Sodium glycocholate; |
| No. of studies | 15 |
|
Relationship between Glycocholic acid and depression (count: 15) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M048 | Type1 | CVS group vs. control group | Serum | Wistar rat | Up |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Serum | Wistar rat | Down |
| Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Serum | Wistar rat | Down |
| Study M1007 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1039 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Down |
| Study M1101 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Up |
| Study M826 | Type1 | CVS group vs. control group | Jejunum | Wistar rat | Down |
| Study M826 | Type1 | CVS group vs. control group | Gut | Wistar rat | Down |
| Study M826 | Type2 | CVS + antibiotic group vs. CVS group | Gut | Wistar rat | Up |
| Study M867 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M867 | Type2 | CUMS + Baihe-Dihuang Tang group vs. CUMS group | Plasma | Sprague-Dawley rat | Unknown |
| Study M883 | Type1 | MDD group vs. control group | Blood | Human | Up |
| Study M907 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M936 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M947 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M947 | Type2 | CUMS + middle dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M947 | Type2 | CUMS + high dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |